Actively Recruiting

Phase Not Applicable
Age: 19Years - 65Years
All Genders
Healthy Volunteers
NCT07498712

Effect of L. Reuteri LM1063 on Sleep Health Improvement

Led by Lactomason Co., Ltd. · Updated on 2026-03-27

80

Participants Needed

1

Research Sites

50 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Purpose: The purpose of this clinical trial is to evaluate the efficacy and safety of Limosilactobacillus reuteri LM1063 on improving sleep health in healthy adults. Based on the microbiota-gut-brain axis, this study aims to scientifically analyze whether the supplementation of this specific probiotic strain can enhance sleep quality. Methodology: This is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 80 participants (40 in the test group and 40 in the control group) will be enrolled. Participants in the test group will consume 500 mg of L. reuteri LM1063 (1.0 x 10\^10 CFU/day) once daily for 8 weeks, while the control group will receive a placebo. Key Evaluations: To assess sleep improvement, various parameters will be measured before and after the 8-week intake period: * Primary Outcomes: Polysomnography (PSG) measures including sleep efficiency (SE), sleep latency (SL), total sleep time (TST), wake after sleep onset (WASO), and delta power; and the Pittsburgh Sleep Quality Index (PSQI). * Secondary Outcomes: Various sleep and stress-related scales (SSS, ESS, PSS, RSQ-W, FSS) and blood biomarkers such as melatonin, GABA, and serotonin levels. * Safety: Monitored through adverse events, vital signs, and clinical laboratory tests.

CONDITIONS

Official Title

Effect of L. Reuteri LM1063 on Sleep Health Improvement

Who Can Participate

Age: 19Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy male or female adults aged 19 to 65
  • Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher
  • Voluntarily agreed to participate and signed the informed consent form
Not Eligible

You will not qualify if you...

  • Severe sleep disorders (Insomnia Severity Index 64 22 or 64 7)
  • Medical conditions causing sleep disorders such as sleep apnea, restless legs syndrome, depression, narcolepsy
  • Intake of medications affecting sleep within 1 month before the first visit
  • Intake of probiotics or fermented milk products within 1 month before the first visit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

P&K Skin Research Center

Seoul, Yeongdeungpo, South Korea, 07236

Actively Recruiting

Loading map...

Research Team

Y

Yu-Na Jung

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here